https://www.selleckchem.com/pr....oducts/Rapamycin.htm
ntom. Further efforts are needed in validation of deform-accumulated dose. Published by Elsevier B.V.BACKGROUND AND PURPOSE High dose-rate (HDR) brachytherapy as monotherapy is a treatment option for localized prostate cancer, but optimal dose and fractionation is unknown. We report efficacy results of a randomized phase II trial of HDR monotherapy delivered as either one or two fractions. MATERIALS AND METHODS Eligible patients had low or intermediate risk prostate cancer, prostate volume less then 60 cc, and no androgen deprivation
Like
Comment
Share
